论文部分内容阅读
目的观察升血灵胶囊联合环孢霉素A(CSA)治疗重型再生障碍性贫血(SAA)的临床疗效。方法收集我院收治的重型再生障碍性贫血62例,其中以升血灵胶囊联合CSA治疗34例为观察组,以单用CSA治疗28例为对照组。通过治疗后患者临床表现、血常规、造血干/祖细胞生长、部分细胞因子水平等指标观察升血灵胶囊的疗效。结果治疗组治疗后有效率为58.8%,对照组治疗后有效率为53.6%,两组疗效无统计学意义(P>0.05)。但治疗组在减轻临床症状,缩短CSA治疗重型再生障碍性贫血的反应时间等方面优于对照组。结论升血灵可以成为SAA治疗中免疫抑制剂的有益补充,体现了中西医结合治疗的优势。
Objective To observe the clinical effects of Shengxiling capsule combined with cyclosporin A (CSA) in the treatment of severe aplastic anemia (SAA). Methods Totally 62 cases of severe aplastic anemia were treated in our hospital. Among them, 34 cases were treated with Sheng Xue Ling Capsule combined with CSA, and 28 cases treated with CSA alone as control group. Through the clinical manifestations of patients after treatment, blood, hematopoietic stem / progenitor cell growth, some cytokines levels and other indicators Shengsheling capsule efficacy. Results After treatment, the effective rate was 58.8% in the treatment group and 53.6% in the control group. There was no significant difference between the two groups (P> 0.05). However, the treatment group was better than the control group in relieving clinical symptoms and shortening the response time of CSA in treating severe aplastic anemia. Conclusion Shengxueling can be a useful supplement for immunosuppressive agents in the treatment of SAA, reflecting the advantages of combining traditional Chinese and Western medicine.